Target: FNIP1
Conjugate: ATTO 594
Product Type: Polyclonal
Immunogen: Synthetic peptide from the mid-protein of Human FNIP1
Swiss-Prot: Q8TF40
Purification: Peptide Affinity Purified
Storage Buffer: 640.91mM DMSO, 136.36mM Ethanolamine, and 9.09mM Sodium Bicarbonate in 90.9% PBS
Concentration: 1 mg/ml
Specificity: Detects ~130 kDa.
Cellular Localization: Cytoplasm
Tissue Specificity: Strong expression is found in the heart, liver placenta, muscle, nasal mucosa, salivary gland and uvula and moderate expression in kidney and lung. Higher levels detected in clear cell renal cell carcinoma (RCC) and chromophobe RCC than in normal kidney tissue.
Scientific Background: Folliculin-interacting protein 1 (FNIP1) is a co-chaperone of HSP90 (1). It Inhibits the ATPase activity of HSP90AA1 leading to reduction in its chaperone activity. It may be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways and may regulate the phosphorylation of RPS6KB1 (2). FNIP1 is strongly expressed in the heart, liver placenta, muscle, nasal mucosa, salivary gland, and uvula. Elevated levels of FNIP1 have been detected in renal cell carcinoma (RCC) (3).
References: 1. Woodford, M. R. et al. (2016) Nature Com. 12037.2. Baba, M. et al. (2006) Proc Natl Acad Sci U.S.A. 103(42):15552-7.3. www.uniprot.org/uniprot/Q8TF45
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
